Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma
Authors
Keywords
-
Journal
Molecular Oncology
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-07-11
DOI
10.1002/1878-0261.13279
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Two novel qualitative transcriptional signatures robustly applicable to non‐research‐oriented colorectal cancer samples with low‐quality RNA
- (2021) Jun Cheng et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Integrated analysis of multimodal single-cell data
- (2021) Yuhan Hao et al. CELL
- Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component
- (2021) Benoit Thibault et al. EMBO Molecular Medicine
- A quantitative score of immune cell infiltration predicts the prognosis in pancreatic ductal adenocarcinoma
- (2021) Zhi-gang Chen et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice
- (2021) Francesca R. Delvecchio et al. Cellular and Molecular Gastroenterology and Hepatology
- Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities
- (2021) Aditi Jain et al. WORLD JOURNAL OF GASTROENTEROLOGY
- An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma
- (2021) Zhijun Xiao et al. Frontiers in Pharmacology
- Identification and Validation of a Malignant Cell Subset Marker-Based Polygenic Risk Score in Stomach Adenocarcinoma Through Integrated Analysis of Bulk and Single-Cell RNA Sequencing Data
- (2021) Qiyuan Zou et al. Frontiers in Cell and Developmental Biology
- Akt inhibitor MK‑2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine
- (2020) Zhanshan Wang et al. Oncology Letters
- A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
- (2020) R. Nicolle et al. ANNALS OF ONCOLOGY
- Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer
- (2019) Thomas B. Karasic et al. JAMA Oncology
- Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology
- (2019) Gregor Sturm et al. BIOINFORMATICS
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- OUP accepted manuscript
- (2018) NUCLEIC ACIDS RESEARCH
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells
- (2017) Hengqiang Zhao et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
- (2017) Marianne Sinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data
- (2017) Julien Racle et al. eLife
- Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression
- (2017) Radim Moravec et al. World Journal of Gastrointestinal Oncology
- An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy
- (2016) Lishuang Qi et al. BRITISH JOURNAL OF CANCER
- TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3
- (2016) Rachel A. Hesler et al. CARCINOGENESIS
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition
- (2016) X Li et al. ONCOGENE
- Pancreatic Cancer Epidemiology, Detection, and Management
- (2016) Qiubo Zhang et al. Gastroenterology Research and Practice
- Integrating Multi-omics Data to Dissect Mechanisms of DNA repair Dysregulation in Breast Cancer
- (2016) Chao Liu et al. Scientific Reports
- Test set bias affects reproducibility of gene signatures
- (2015) Prasad Patil et al. BIOINFORMATICS
- Gemcitabine resistance in pancreatic ductal adenocarcinoma
- (2015) Yoav Binenbaum et al. DRUG RESISTANCE UPDATES
- Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
- (2014) A. P. Patel et al. SCIENCE
- Translesion DNA Synthesis and Mutagenesis in Eukaryotes
- (2013) J. E. Sale Cold Spring Harbor Perspectives in Biology
- Re: A DNA Repair Pathway-Focused Score for Prediction of Outcomes in Ovarian Cancer Treated with Platinum-Based Chemotherapy
- (2012) O. A. Stefansson et al. JNCI-Journal of the National Cancer Institute
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- Exploring Protein Kinase Inhibitors
- (2012) Young Bin Hong et al. PANCREAS
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search